25+ Active Companies working to develop 50+ Pipeline Therapies for Medical Marijuana Treatment Landscape | Major Companies- Corbus Pharmaceuticals, Jazz Pharmaceuticals, Zynerba Pharmaceuticals, and Others.

DelveInsight's, "Medical Marijuana Pipeline Insight 2023," report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Medical Marijuana pipeline report

• DelveInsight's Medical Marijuana pipeline analysis depicts a robust space with 25+ active players working to develop 50+ Medical Marijuana pipeline treatment therapies.

• The leading Medical Marijuana Companies include Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, Jazz Pharmaceuticals, Medlab Clinical, Zynerba Pharmaceuticals, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Botanix Pharmaceuticals, Arena Pharmaceuticals, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Emerald Health Pharmaceuticals, MGC Pharmaceuticals, Echo Pharmaceuticals, Centrexion Therapeutics, Tilray, Artelo Biosciences, BOL Pharma, One World, Receptor Life Sciences, AXIM Biotechnologies, Serina Therapeutics, EPM Group, GB Sciences, Cannovex, e3D Pharma, Phytecs, Zelira Therapeutics, Pascal Biosciences, Enveric Biosciences, MyMD Pharmaceuticals, Neuropathix, Can-Fite Pharma, Skye Bioscience, Vitality Biopharma, SciCann Therapeutics, Renew Biopharma, Aequus Pharmaceuticals, CURE Pharmaceuticals, Demeetra AgBio, and several others.

• Promising Medical Marijuana pipeline therapies include Lenabasum, BX-1, Nabiximols, NanaBis, Zygel, THX-110, A1002N5S, BTX 1801, Olorinab, Dronabinol, VSN16R, INM-755, BTX 1503, CBBD50, EHP-101, CannEpil, CogniCann, Namisol, CNTX-6016, TN-TC11G, EV101, ART27.13, BOL-DP-o-08, BTX 1702, RLS102, RLS103, SER-228, EPM301, EPM305, EPM306, GBS.CP110, GBS.CP121, OCT-461201, CNX-001, CNX-002, CNX-003, CS-NEURO-1, CBIS-LC-001, CBIS-PC-001, CBIS-PPC-001, e3D-03, e3D-05, PECS-202, CBIS-OS-001, CBIS-SSA-001, MEM.PD119, PECS-101, PECS-112, PAS-403, PAS-393, KLS-13019, CNX-004, INM-088, EPM302, VBX-100, PLP-33, TopiCann, EPM303, EPM311, OWC-1808, and others

Request a sample and discover the recent advances in Medical Marijuana Drug Treatment @ Medical Marijuana Pipeline Report- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Overview
The term Medical Marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions. The US FDA has not recognized or approved the marijuana plant as medicine.

Recent Developmental Activities in the Medical Marijuana Treatment Landscape

• In June 2022, Zynerba Pharmaceuticals, Inc., presented an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022) that was held from May 31 - June 3, 2022. The presentation titled, "Long-Term Safety and Sustained Efficacy of ZYN002 Cannabbidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)," includes data demonstrating that in the ongoing long-term safety and efficacy trial of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the greatest improvement in patients with complete methylation of their FMR1 gene.

• In May 2022, Corbus Pharmaceuticals announced that the National Institutes of Health sponsored Phase 2 study of lenabasum in systemic lupus erythematosus had completed its last patient visit and the clinical database had been locked. The Company is awaiting topline results. Corbus is pursuing potential partnerships to fund further development of lenabasum.

• In May 2022, Tetra Bio-Pharma Inc. announced that the European Medicines Agency (EMA) has classified PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). The designation represents PPP004's third orphan drug designation (ODD) as a treatment for EB.

• In January 2022, Emerald Health Pharmaceuticals Inc. received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to begin enrolling patients in its Phase 2a clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (RMS), specifically relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

• Pfizer Inc. and Arena Pharmaceuticals, Inc. announced on the 13th of December 2021, that the companies had entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for the modest price of $6.7 billion. The boards of directors of both companies have unanimously approved the transaction. The deal is now expected to close in the first half of 2022, pending regulatory approvals.

• In May 2021, Jazz Pharmaceuticals announced the completion of its acquisition of GW Pharmaceuticals plc, a leader in the science, development and commercialization of cannabbinoid-based prescription medicines.

• In August 2021, MediPharm Labs Corp. announced that the Company's research partner McMaster University (the "Researcher") had received a no objection letter from Health Canada to proceed with research with MediPharm Labs CBBD50 and CBBD10:2. This is a key milestone in moving forward with the Company's strategy to be the go-to partner for pharmaceuticals containing

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Medical Marijuana Pipeline Report @ Latest Medical Marijuana Drugs Launch- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Cannabbidiol Emerging Drugs

• BX-1: Bionorica SE
BX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of Δ⁹-THHC, the primary psychoactive component. The drug is currently in phase III stage of development for the treatment of spasticity in patients with multiple sclerosis not showing sufficient response to their current anti-spasticity treatment.

• Lenabasum: Corbus Pharmaceuticals
Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabbinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells.

• THX-110: Therapix Biosciences
THX-110 is a being developed by Therapix Biosciences. The drug candidate platform is for the treatment of symptoms related to Tourette syndrome (TS), as well as obstructive sleep apnea (OSA) and chronic pain. Therapix is seeking orphan drug designation for this compound. The THX-110 program takes a unique approach to cannabbinoid formulation using the Entourage Effect hypothesis (i.e., in which endocannabbinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. The drug is currently in phase II stage of development.

• Cannabeis oil: TO Pharmaceuticals
TO Pharma is developing next-generation cannabbinoid therapies for debilitating diseases. TO pharmaceuticals is developing Cannabeis oil, and currently, it is in phase II stage of development for the treatment of hidradenitis suppurativa and agitation related to dementia. The cannabeis oil is made out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THHC) and Cannabbidiol (CBBD) in a 1:20 ratio and at a concentration of 30% CBBD and 1.5% Δ9-THHC. Each Avidekel oil drop is approximately 0.04 mL in volume containing about 12 mg CBBD and 0.6 mg Δ9-THHC. The oil is in the form of drops to be administered orally.

• VSN16R: Canbex Therapeutics
VSN16R is currently in phase II stage of development for the treatment of spasticity in people with multiple sclerosis. The orally active small molecule compound is being developed by Canbex Therapeutics, a spin-off of University College London (UCL). Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial. In the Phase I study, 72 healthy volunteers were enrolled in a placebo-controlled, single ascending- and multiple-ascending dose design.

• INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product. The Phase 2 study, 755-201-EB, is designed to enroll up to 20 patients, conservatively within 10-12 months, and will take place at 10 pre-qualified clinical sites in several countries. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period.

Medical Marijuana Pipeline Therapeutic Assessment
There are approx. 25+ key companies which are developing the therapies for Medical Marijuana - Cannabbidiol. The companies which have their Medical Marijuana - Cannabbidiol drug candidates in the most advanced stage, i.e. Phase III include, Bionorica SE.

Learn more about the emerging Medical Marijuana pipeline therapies @ Medical Marijuana Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Medical Marijuana Pipeline Report

• Coverage: Global

• Medical Marijuana companies: Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, Jazz Pharmaceuticals, Medlab Clinical, Zynerba Pharmaceuticals, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Botanix Pharmaceuticals, Arena Pharmaceuticals, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Emerald Health Pharmaceuticals, MGC Pharmaceuticals, Echo Pharmaceuticals, Centrexion Therapeutics, Tilray, Artelo Biosciences, BOL Pharma, One World Cannabeis, Receptor Life Sciences, AXIM Biotechnologies, Serina Therapeutics, EPM Group, GB Sciences, Cannovex, e3D Pharma, Phytecs, Zelira Therapeutics, Pascal Biosciences, Enveric Biosciences, MyMD Pharmaceuticals, Neuropathix, Can-Fite Pharma, Skye Bioscience, Vitality Biopharma, SciCann Therapeutics, Renew Biopharma, Aequus Pharmaceuticals, CURE Pharmaceuticals, Demeetra AgBio, and others.

• Medical Marijuana pipeline therapies: Lenabasum, BX-1, Nabiximols, NanaBis, Zygel, THX-110, A1002N5S, BTX 1801, Olorinab, Dronabinol, VSN16R, INM-755, BTX 1503, CBBD50, EHP-101, CannEpil, CogniCann, Namisol, CNTX-6016, TN-TC11G, EV101, ART27.13, BOL-DP-o-08, BTX 1702, RLS102, RLS103, SER-228, EPM301, EPM305, EPM306, GBS.CP110, GBS.CP121, OCT-461201, CNX-001, CNX-002, CNX-003, CS-NEURO-1, CBIS-LC-001, CBIS-PC-001, CBIS-PPC-001, e3D-03, e3D-05, PECS-202, CBIS-OS-001, CBIS-SSA-001, MEM.PD119, PECS-101, PECS-112, PAS-403, PAS-393, KLS-13019, CNX-004, INM-088, EPM302, VBX-100, PLP-33, TopiCann, EPM303, EPM311, OWC-1808, and others.

Dive deep into rich insights for drugs for Medical Marijuana Market Drivers and Medical Marijuana Market Barriers, click here @ Medical Marijuana Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Medical Marijuana - Cannabbidiol: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. BX-1: Bionorica SE
8. Mid Stage Products (Phase II)
9. THX-110: Therapix Biosciences
10. Early stage products (Phase I/II)
11. CNTX 6016: Centrexion Therapeutics
12. Inactive Products
13. Medical Marijuana - Cannabbidiol Key Companies
14. Medical Marijuana - Cannabbidiol Key Products
15. Medical Marijuana - Cannabbidiol- Unmet Needs
16. Medical Marijuana - Cannabbidiol- Market Drivers and Barriers
17. Medical Marijuana - Cannabbidiol- Future Perspectives and Conclusion
18. Medical Marijuana - Cannabbidiol Analyst Views
19. Medical Marijuana - Cannabbidiol Key Companies
20. Appendix

Got Queries? Find out the related information on Medical Marijuana Mergers and acquisitions, Medical Marijuana Licensing Activities @ Medical Marijuana Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthhcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.